Beyond the hallmarks of cancer: enabling technologies reshaping cancer diagnosis, prevention, and treatment.

IF 4 Q2 ONCOLOGY
Oncology Reviews Pub Date : 2026-08-04 eCollection Date: 2026-01-01 DOI:10.3389/or.2026.1804447
Sarfaraz K Niazi
{"title":"Beyond the hallmarks of cancer: enabling technologies reshaping cancer diagnosis, prevention, and treatment.","authors":"Sarfaraz K Niazi","doi":"10.3389/or.2026.1804447","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer biology has been organized for 2 decades by the hallmarks framework, articulated in 2000 and most recently revised in 2026. The pace of technological change in oncology now requires reframing how cancer is detected, prevented, and treated. This review argues that the hallmarks framework, while historically essential, is no longer sufficient on its own to capture contemporary cancer care, and repositions the discussion around enabling technologies that operate across and beyond individual hallmarks. For diagnosis, multi-omic liquid biopsy, AI-assisted radiomics and digital pathology, spatial transcriptomics, single-cell sequencing, and machine-learning analysis of plasma proteomics now support earlier detection, prediction of cancer risk years before diagnosis, monitoring of clonal evolution, and prediction of treatment response. For prevention, the validated population-level success of Human papillomavirus and HBV vaccination is contrasted with investigational directions including mRNA platforms, CRISPR-enabled antigen optimization, personalized neoantigen prophylaxis, and biomarker-stratified molecular interception, none of which has yet been validated in prospective human cancer-prevention trials. For treatment, the discussion is organized by modality class: immune checkpoint inhibitors and resistance strategies, antibody-drug conjugates, bispecific antibodies and T-cell engagers, radioligand therapies, tumor-infiltrating lymphocyte therapy, CRISPR-edited CAR-T and TCR therapies, photonic and photoimmunologic therapies, RNA therapeutics, and adaptive combination regimens. Comparative tables summarize diagnostic platforms, immunotherapeutic modalities, photonic therapies, CRISPR-edited immunotherapy trials, neoantigen vaccine pipelines, and convergent strategies. The trajectory of oncology will be defined less by incremental refinement of hallmarks and more by convergent technologies that integrate diagnostics, prevention, and treatment into continuous, data-driven systems.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"20 ","pages":"1804447"},"PeriodicalIF":4.0000,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13481877/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/or.2026.1804447","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer biology has been organized for 2 decades by the hallmarks framework, articulated in 2000 and most recently revised in 2026. The pace of technological change in oncology now requires reframing how cancer is detected, prevented, and treated. This review argues that the hallmarks framework, while historically essential, is no longer sufficient on its own to capture contemporary cancer care, and repositions the discussion around enabling technologies that operate across and beyond individual hallmarks. For diagnosis, multi-omic liquid biopsy, AI-assisted radiomics and digital pathology, spatial transcriptomics, single-cell sequencing, and machine-learning analysis of plasma proteomics now support earlier detection, prediction of cancer risk years before diagnosis, monitoring of clonal evolution, and prediction of treatment response. For prevention, the validated population-level success of Human papillomavirus and HBV vaccination is contrasted with investigational directions including mRNA platforms, CRISPR-enabled antigen optimization, personalized neoantigen prophylaxis, and biomarker-stratified molecular interception, none of which has yet been validated in prospective human cancer-prevention trials. For treatment, the discussion is organized by modality class: immune checkpoint inhibitors and resistance strategies, antibody-drug conjugates, bispecific antibodies and T-cell engagers, radioligand therapies, tumor-infiltrating lymphocyte therapy, CRISPR-edited CAR-T and TCR therapies, photonic and photoimmunologic therapies, RNA therapeutics, and adaptive combination regimens. Comparative tables summarize diagnostic platforms, immunotherapeutic modalities, photonic therapies, CRISPR-edited immunotherapy trials, neoantigen vaccine pipelines, and convergent strategies. The trajectory of oncology will be defined less by incremental refinement of hallmarks and more by convergent technologies that integrate diagnostics, prevention, and treatment into continuous, data-driven systems.

超越癌症的特征:使能技术重塑癌症的诊断、预防和治疗。
20年来,癌症生物学一直是由一个标志性框架组织起来的,这个框架于2000年提出,最近一次修订是在2026年。肿瘤学技术变革的步伐现在要求重新规划癌症的检测、预防和治疗方式。这篇综述认为,虽然标志框架在历史上是必不可少的,但它本身已不足以捕捉当代癌症治疗,并重新定位了围绕跨个体标志和超越个体标志的使能技术的讨论。在诊断方面,多组学液体活检、人工智能辅助放射组学和数字病理学、空间转录组学、单细胞测序和血浆蛋白质组学的机器学习分析现在支持早期检测、诊断前癌症风险预测、克隆进化监测和治疗反应预测。在预防方面,与mRNA平台、crispr激活抗原优化、个性化新抗原预防和生物标志物分层分子拦截等研究方向进行了对比,证实了人群水平上人乳头瘤病毒和HBV疫苗接种的成功,但这些研究方向尚未在前瞻性人类癌症预防试验中得到验证。对于治疗,讨论是按模式类组织的:免疫检查点抑制剂和耐药策略,抗体-药物偶联物,双特异性抗体和t细胞接合物,放射配体治疗,肿瘤浸润淋巴细胞治疗,crispr编辑的CAR-T和TCR治疗,光子和光免疫治疗,RNA治疗和适应性联合方案。比较表总结了诊断平台、免疫治疗方式、光子疗法、crispr编辑的免疫治疗试验、新抗原疫苗管道和趋同策略。肿瘤学的发展轨迹将更少地由不断改进的特征来定义,更多地由融合诊断、预防和治疗的技术来定义,这些技术将集成到连续的、数据驱动的系统中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology Reviews
Oncology Reviews ONCOLOGY-
CiteScore
6.30
自引率
0.00%
发文量
9
审稿时长
9 weeks
期刊介绍: Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书